GCTKGCTKHealthcare · Medical Devices

GCTK Stock Forecast: GlucoTrack, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$1.39
−32.20% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 29 Oct 2026 — in the weakest quartile.

Market cap
$216,693.00
Ticker Nerd rank
11/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$3.4M
Net income−$3.8M
Free cash flow−$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+16.0%
1M
−60.1%
YTD
−98.8%
1Y
−99.3%
From 52W high
−99.3%
From 52W low
+72.5%
$1
$204
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores GlucoTrack, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Oct 2026
11/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
79
Accruals
30
Revisions
25
Momentum
24
Volatility
9
Value
6
Quality
6
Issuance
2

Growth (79): Sales and profits are climbing, and climbing faster than before.

Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GCTK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GCTK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200Jan 26Apr 26Jul 26Oct 26GCTK

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

GCTK appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GCTK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, GlucoTrack, Inc. returned −99.3% against +13.1% for the S&P 500, dividends included.

GCTK vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26GCTKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GCTK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−164.4%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GlucoTrack, Inc. has a market value of $217K and an enterprise value of $900K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$15.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$16.3M.

  • Shares outstanding: 6.6M.

  • GlucoTrack, Inc. employs 15 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

GCTK and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
GCTKGlucoTrack, Inc.$216,693.0011
CODXCo-Diagnostics, Inc.$1.7M32
NXLNexalin Technology, Inc.$1.7M24
ADGMAdagio Medical Holdings, Inc.$1.7M24
AMIXAutonomix Medical, Inc.$1.7M31
VVOSVivos Therapeutics, Inc.$1.8M43
PFSAProfusa, Inc.$1.8M19

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own GlucoTrack, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about GCTK

How does Ticker Nerd's model rank GCTK?

As at 29 Oct 2026, GlucoTrack, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).

What is the GCTK stock forecast for 2030?

No analyst covering GlucoTrack, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GCTK are extrapolating price history, which says nothing about the business.

How has GCTK stock performed over the past year?

GlucoTrack, Inc. returned -99.3% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GlucoTrack, Inc. do?

GlucoTrack Inc. is a medical technology company focused on diabetes monitoring solutions. GlucoTrack Inc. develops devices and systems designed to measure blood glucose levels for people living with diabetes, with an emphasis on continuous monitoring and reduced reliance on traditional finger-stick testing.

Company

About GlucoTrack, Inc.

GlucoTrack Inc. is a medical technology company focused on diabetes monitoring solutions. GlucoTrack Inc. develops devices and systems designed to measure blood glucose levels for people living with diabetes, with an emphasis on continuous monitoring and reduced reliance on traditional finger-stick testing. Its current work centers on non-invasive glucose monitoring technology and an investigational long-term implantable continuous blood glucose monitor intended for ongoing glycemic tracking. The company’s products and development programs are aimed at supporting patients with Type 1 diabetes, insulin-dependent Type 2 diabetes, and prediabetes, while also serving clinicians who manage these conditions. GlucoTrack Inc. operates within the healthcare equipment and medical device market, where glucose monitoring tools play a critical role in daily diabetes care and disease management. The company is headquartered in Rutherford, New Jersey.

CEO Mr. Erik C. Emerson · 15 employees · United States · https://glucotrack.com